Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stine Rasch1, Charlotte Toftmann Hansen1, Niels Abilgaard1,2

  • 1Hæmatologisk Afdeling, Odense Universitetshospital.

Ugeskrift for Laeger
|August 8, 2024
PubMed
Summary
This summary is machine-generated.

Serum-free light chain (S-FLC) analysis is crucial for diagnosing M-protein-related disorders like multiple myeloma. Current guidelines recommend S-FLC testing, but limited access in some Danish regions may lead to missed diagnoses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitigating Teclistamab Toxicity: Prophylactic Tocilizumab and Timing of Immunoglobulin Replacement Therapy in a Nationwide Cohort.

American journal of hematology·2026
Same author

REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials.

Haematologica·2026
Same author

An Accelerated Sonication-Assisted Preparation method for mass spectrometry-based identification of subtype specific amyloidogenic proteins in fat aspirates.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis·2025
Same author

Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study.

Blood neoplasia·2025
Same author

Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): Characteristics and risk factors in a Danish nationwide population-based study.

British journal of haematology·2025
Same author

Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Haematologica·2024

Area of Science:

  • Hematology
  • Clinical Chemistry
  • Diagnostic Immunology

Background:

  • Current guidelines recommend serum M-protein and serum-free light chain (S-FLC) analysis for suspected M-protein-related disorders.
  • Measuring only serum M-protein risks overlooking many multiple myeloma patients.
  • General practitioners in some Danish regions lack access to S-FLC testing.

Purpose of the Study:

  • To review and disseminate knowledge regarding serum-free light chain (S-FLC) analysis.
  • To discuss the applicability and limitations of S-FLC analysis in diagnosing monoclonal gammopathies.
  • To highlight the diagnostic implications of restricted S-FLC access for primary care physicians.

Main Methods:

  • Literature review of studies on M-protein-related disorders and S-FLC analysis.

Related Experiment Videos

  • Analysis of current diagnostic guidelines and their implementation.
  • Discussion of clinical case scenarios illustrating the importance of S-FLC.

    • Main Results:

    • S-FLC analysis significantly improves the detection rate of monoclonal gammopathies compared to M-protein alone.
    • Exclusion of S-FLC testing can lead to delayed or missed diagnoses of multiple myeloma and related disorders.
    • Restricted access to S-FLC testing poses a barrier to optimal patient care in affected regions.

    Conclusions:

    • Serum-free light chain analysis is an essential component in the diagnostic workup of suspected monoclonal gammopathies.
    • Ensuring widespread availability of S-FLC testing is critical for accurate and timely diagnosis.
    • Addressing disparities in diagnostic test access is necessary to improve patient outcomes for M-protein-related disorders.